Author

Aroon Supramaniam

Griffith UniversityORCID 0000-0002-6251-2461Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

Adi IdrisiD· 2 shared Alicia M. DavisiD· 1 shared Alişan KayaböleniD· 1 shared Arda OdabasiD· 1 shared Ayşegul Durgun· 1 shared Canan Bayraktar-OdabasiD· 1 shared Christopher L. D. McMillaniD· 1 shared Citradewi SoemardyiD· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Adi IdrisORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioengineeringInternational Journal of NanomedicinePeer-reviewedJul 1, 2024

ACE2-Coated Virus-Like Particles Effectively Block SARS-CoV-2 Infection

Canan Bayraktar-Odabas, Alişan Kayabölen, Arda Odabas…·Tugba Bagci Onder

This paper develops ACE2-coated virus-like particles (ACE2-VLPs) that effectively neutralize SARS-CoV-2, including variants, and show superior efficacy compared to ACE2-expressing extracellular vesicles.

5 citations

experimental assayhost-pathogen & immune response

𝕏 PostBluesky

Synthetic BiologyMolecular TherapyPeer-reviewedMay 13, 2021

A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19

Adi Idris, Alicia M. Davis, Aroon Supramaniam…·Kevin V. Morris

This paper develops an siRNA-nanoparticle therapy targeting SARS-CoV-2 that reduces viral load and improves survival in mice.

165 citationstop 1%

humanexperimental assay

𝕏 PostBluesky